Proteasome Inhibitor or Immunomodulators Which is The Optimal Maintenance For Newly Diagnosed Multiple Myeloma: A 7-Year Real-World Data in China.

Xiaoyan Han, Chunxiang Jin, Gaofeng Zheng, Donghua He, Yi Zhao, Yi Li, Wenjun Wu, Weiyan Zheng, Guoqing Wei, Enfan Zhang, He Huang, Jingsong He, Zhen CaiResearch Square 2021 · DOI

Introduction

Multiple myeloma (MM) is a hematologic malignancy characterized by a pattern of remission and inevitable relapse. While induction therapy and autologous stem cell transplantation (ASCT) have significantly improved initial outcomes, maintenance therapy—long-term, low-dose treatment following consolidation—is now a standard of care to deepen clinical response and delay disease progression.

However, clinical uncertainty remains regarding the optimal drug class for maintenance. The two primary options are Proteasome Inhibitors (PIs), such as bortezomib, and Immunomodulators (IMiDs), such as thalidomide or lenalidomide. Additionally, the ideal duration of maintenance therapy remains a subject of debate, balancing long-term efficacy against cumulative toxicity. This study provides real-world evidence from a 7-year Chinese cohort to address these critical clinical questions.

Methods

This retrospective study analyzed 226 patients with newly diagnosed multiple myeloma (NDMM) treated at the First Affiliated Hospital of Zhejiang University between 2013 and 2018. Patients were stratified by disease stage using the International Staging System (ISS), Revised ISS (R-ISS), and Durie-Salmon (DS) criteria.

The cohort was divided into those receiving maintenance therapy (n=181) and those who did not (n=45). Within the maintenance group, 127 patients received PI-based regimens (primarily bortezomib) and 54 received IMiDs. Survival outcomes, including Progression-Free Survival (PFS) and Overall Survival (OS), were analyzed using Kaplan-Meier curves. The study also evaluated the impact of maintenance duration, comparing outcomes for treatment periods of <12 months, 12–24 months, and >24 months.

Results

Survival Outcomes and Comparative Efficacy

Maintenance therapy significantly improved survival across the cohort. The median PFS for the maintenance group was 41.1 months compared to 10.5 months for the no-maintenance group (p < 0.001). Median OS was not reached in the maintenance group, while it was 38.6 months in the control group (p < 0.001).

When comparing drug classes, bortezomib-based maintenance demonstrated a clear advantage over IMiDs. The median PFS was 43.7 months for the PI group versus 38.5 months for the IMiD group (p = 0.034). Similarly, OS was significantly improved with PI maintenance (median not reached vs. 78.5 months, p = 0.041).

Survival curves comparing maintenance vs. no maintenance and PI-based vs. IMiD-based maintenance.

Response Upgrading and Subgroup Benefits

Maintenance therapy did more than just sustain remission; it actively deepened the clinical response. Patients receiving maintenance were significantly more likely to "upgrade" their response (e.g., from Partial Response to Very Good Partial Response or better) compared to the control group (34.3% vs. 13.3%, p = 0.006).

Subgroup analysis revealed that the benefits of bortezomib-based maintenance were most pronounced in high-risk patients (ISS 2-3 and R-ISS 2-3) and younger patients (<65 years). For high-risk patients in ISS stages 2-3, PI maintenance achieved a 3-year PFS of 57.0%, compared to 40.3% for those on IMiDs.

Optimal Duration of Therapy

The study identified a "sweet spot" for treatment duration. While receiving maintenance for at least 12 months dramatically improved survival compared to shorter durations (5-year OS of 91.9% vs. 51.1%), there was no statistically significant difference in survival between patients treated for 12–24 months and those treated for more than 24 months (p = 0.292).

Discussion and Conclusion

This real-world study confirms that maintenance therapy is essential for improving survival in NDMM. Bortezomib-based regimens appear superior to IMiDs, particularly for high-risk and younger patient populations. Furthermore, the data suggests that a maintenance duration of 12 to 24 months may provide a satisfactory balance between efficacy and treatment burden.

Limitations of the study include its retrospective nature and the relatively small size of the IMiD and control subgroups. Future research should explore the role of newer oral PIs, such as ixazomib, which may offer similar survival benefits with improved patient compliance and reduced toxicity. Additionally, the integration of Minimal Residual Disease (MRD) monitoring will be crucial for personalizing the duration of maintenance therapy in the future.

Summary updated

Abstract

<title>Abstract</title> <bold>Background:</bold> According to different patients’ subgroups choose optimal maintenance therapy. <bold>Methods: </bold>226 Newly Diagnosed Multiple Myeloma (NDMM) patients in our center were included, the patients’ characteristics, survival, response, subgroup analysis, adverse reactions were compared between the patients with or without maintenance, proteasome inhibitor (PI) or immunomodulators (IMiDs) maintenance. And the survival of different maintenance duration of bortezomib-based regimens was also analyzed.<bold>Results: T</bold>he maintenance therapy not only upgraded more patients’ response (34.3 vs. 13.3%, p= 0.006), but also significantly prolonged the patients’ PFS (median PFS: 41.1 vs. 10.5 months, p &lt; 0.001) and OS (median OS: not reached vs. 38.6 months, p &lt; 0.001). Compared with IMiDs, the PFS (median PFS: 43.7 vs. 38.5 months, p = 0.034) and OS (median OS: not reached vs. 78.5 months, p = 0.041) can both benefit from bortezomib-based maintenance. The patients younger than 65 years old with bortezomib-based maintenance significantly prolonged the OS (p= 0.032). Patients achieving the only partial response (PR) after induction and consolidation therapy experienced a significantly longer PFS and OS with bortezomib-based maintenance compared to IMiDs (p= 0.007, 0.002). Besides, the high-risk patients (ISS 2-3, DS 2-3 and RISS 2-3) with bortezomib-based maintenance can benefit PFS (p= 0.002, 0.02, 0.06, respectively) and OS (p=0.059, 0.047, 0.044, respectively) compared with IMiDs. The OS was significantly prolonged in the patients who received ≥12 months of bortezomib-based maintenance than those with maintenance &lt; 12 months (p&lt; 0.001), but no difference was observed in OS between the patients who received the 12-24 or ≥ 24months of bortezomib-based maintenance (p= 0.292).<bold>Conclusion:</bold> Maintenance therapy can significantly improve the survival of NDMM patients. Bortezomib-based regimens maintenance was more superior to IMiDs in overall PFS and OS. The beneficial effect is most evident in patients achieving the only PR after induction and consolidation therapy, and the high-risk patients. Moreover, younger patients also could benefit from bortezomib-based maintenance in OS. The bortezomib-based maintenance duration lasting 12-24 months after induction and consolidation therapy can reach a satisfactory OS.
BibTeX
@inproceedings{han2021proteasome,
  author = {Xiaoyan Han and Chunxiang Jin and Gaofeng Zheng and Donghua He and Yi Zhao and Yi Li and Wenjun Wu and Weiyan Zheng and Guoqing Wei and Enfan Zhang and He Huang and Jingsong He and Zhen Cai},
  title = {{Proteasome Inhibitor or Immunomodulators Which is The Optimal Maintenance For Newly Diagnosed Multiple Myeloma: A 7-Year Real-World Data in China.}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-205639/v1},
}
Figure